MicroRNA markers screening and early clinical prediction of ovarian cancer in breast cancer patients
WU Long1 LIU Chen1 JIANG Hongchuan2 LI Jie2 ZHENG Jiyan3 SHEN Ye3 DUAN Demin3▲ WANG Shuzhen1▲
1.Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China;
2.Department of Breast Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China;
3.Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
Abstract：Objective To investigate the differential expression of microRNAs and their correlation in patients with ovarian cancer after breast cancer operation by miRNA microarray, and to provide early prediction of postoperative ovarian cancer. Methods The patients with ovarian cancer who were admitted to Beijing Chaoyang Hospital, Capital Medical University from January 2000 to December 2014 were enrolled as research objects. The patients with ovarian cancer after breast cancer surgery were regarded as experimental group, patients with complication of benign gynecological tumors followed by breast cancer (benign control group) and patients with no any abnormal after breast cancer surgery (single breast cancer control group) were regarded as control. The miRNA microarray and qRT-PCR were used to detect the differentially expressed miRNA levels among the groups. Results A series of differentially expressed miRNAs were detected by miRNA microarray, among which miR-1234 was the most significantly differentially expressed, and the results of verification of miR-1234 expression by qRT-PCR also showed that the expression level of miR-1234 in the experimental group was significantly higher than that in the benign control group and the single breast cancer control group (P ＜ 0.05). The sensitivity and specificity of early prediction of ovarian cancer after breast cancer surgery by using miR-1234 were 80%. Conclusion miR-1234 is the most obvious difference between patients with ovarian cancer after breast cancer surgery and those without ovarian cancer after breast cancer surgery. It is expected to be a tumor marker for early prediction of ovarian cancer after breast cancer operation.
吴龙1 刘晨1 蒋宏传2 李杰2 郑继燕3 沈叶3 段德民3▲ 王淑珍1▲. 乳腺癌术后并发卵巢癌的microRNA标志物筛选及临床早期预测研究[J]. 中国医药导报, 2019, 16(7): 15-19.
WU Long1 LIU Chen1 JIANG Hongchuan2 LI Jie2 ZHENG Jiyan3 SHEN Ye3 DUAN Demin3▲ WANG Shuzhen1▲. MicroRNA markers screening and early clinical prediction of ovarian cancer in breast cancer patients. 中国医药导报, 2019, 16(7): 15-19.
[1] Siegel R，Naishadham D，Jemal A. Cancer statistics，2012 [J]. CA Cancer J Clin，2012，62（1）：10-29.
[2] Torre LA，Bray F，Siegel RL，et al. Global cancer statistics，2012 [J]. CA Cancer J Clin，2015，65（2）：87-108.
[3] 刘晨，吴龙，王淑珍，等.乳腺癌术后并发妇科生殖道恶性肿瘤的高危因素分析[J].首都医科大学学报，2017，38（1）：92-96.
[4] Marsh D，Zori R. Genetic insights into familial cancers--update and recent discoveries [J]. Cancer Lett，2002，181（2）：125-164.
[5] Ramus SJ，Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer [J]. Mol Oncol，2009，3（2）：138-150.
[6] Sogaard M，Kjaer SK，Gayther S，et al. Ovarian cancer and genetic susceptibility in relation to the BRCA1 and BRCA2 genes. Occurrence，clinical importance and intervention [J]. Acta Obstet Gynecol Scand，2006，85（1）：93-105.
[7] Pilarski R，Patel DA，Weitzel J，et al. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer [J]. PLoS One，2012，7（5）：e37891.
[8] Pelttari LM，Heikkinen T，Thompson D，et al. RAD51C is a susceptibility gene for ovarian cancer [J]. Hum Mol Genet，2011，20（16）：3278-3288.
[9] Antoniou A，Pharoah PD，Narod S，et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history：a combined analysis of 22 studies [J]. Am J Hum Genet，2003，72（5）：1117-1130.
[10] Nelson HD，Huffman LH，Fu R，et al. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility：Systematic Evidence Review for the U.S. Preventive Services Task Force [J]. Ann Intern Med，2005，143（5）：355-361.
[11] Berry DA，Parmigiani G，Sanchez J，et al. Probability of Carrying a Mutation of Breast-Ovarian Cancer Gene BRCA1 Based on Family History [J]. J Natl Cancer Inst，1997， 89（3）：227-238.
[12] Kapoor NS，Banks KC. Should multi-gene panel testing replace limited BRCA1/2 testing? A review of genetic testing for hereditary breast and ovarian cancers [J]. World Journal of Surgical Procedures，2016，6（1）：13.
[13] Shen J，Wang D，Gregory SR，et al. Evaluation of microRNA expression profiles and their associations with risk alleles in lymphoblastoid cell lines of familial ovarian cancer [J]. Carcinogenesis，2012，33（3）：604-612.
[14] Suryawanshi S，Vlad AM，Lin HM，et al. Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer [J]. Clin Cancer Res，2013， 19（5）：1213-1224.
[15] Zhou H，Guo JM，Lou YR，et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker [J]. J Mol Med（Berl），2010，88（7）：709-717.
[16] 陈荣，刘光辉，周总光.外周血microRNA作为肿瘤标志物的研究进展[J].中国普外基础与临床杂志，2012， 19（9）：1020-1023.
[17] Taylor DD，Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer [J]. Gynecol Oncol，2008，110（1）：13-21.
[18] Kiss O，T■kés AM，Spisák S，et al. Breast- and salivary gland-derived adenoid cystic carcinomas：potential post-transcriptional divergencies. A pilot study based on miRNA expression profiling of four cases and review of the potential relevance of the findings [J]. Pathol Oncol Res，2015，21（1）：29-44.
[19] Högfeldt T，Johnsson P，Grandér D，et al. Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas [J]. Leuk Lymphoma，2014， 55（5）：1158-1165.
[20] Rosen DG，Mercado-Uribe I，Yang G，et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis [J]. Cancer，2006，107（11）：2730-2740.
[21] Duan Z，Foster R，Bell DA，et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer [J]. Clin Cancer Res，2006，12（17）：5055-5063.
[22] Silver DL，Naora H，Liu J，et al. Activated signal transducer and activator of transcription STAT3：localization in focal adhesions and function in ovarian cancer cell motility [J]. Cancer Res，2004，64（10）：3550-3558.
2019, Vol. 16 
京公网安备 11010502046598号